BedMed is our first large pragmatic trial. As of June 2022, 428 family physicians and 7 nurse practitioners from 5 Canadian provinces have recruited roughly 3,357 participants. Like INRange, BedMed is about medication timing. In particular this project is designed to determine if switching the time of day blood pressure medications is taken to bedtime (compared to conventional morning use) reduces death, stroke, heart attack or hospital admission for congestive heart failure.
Blood pressure (BP) normally exhibits a circadian rhythm, with relatively lower pressures during sleep1. Lack of this sleep time “dip” correlates strongly with adverse cardiovascular events and BP correlates most strongly with such events when measured at night (i.e. during sleep)2-5. Motivated by such observations, Spanish researchers studied the effect of taking BP medication at bedtime (when the effect on nighttime BP would be greatest) versus conventional morning use (when virtually all BP meds are taken). The results of this study (the MAPEC trial) were striking6. Over a median 5.6 years follow-up, adverse cardiovascular events occurred in 187 of 1084 subjects taking BP medication in the morning but only 68 of 1072 subjects who took their BP medication at bedtime (relative risk 0.39, 95%CI [0.29-0.51], p < 0.001). This 61% reduction in adverse events was similar for all individual components of the primary outcome (including death from all causes, stroke, myocardial infarction, new angina pectoris, heart failure and occlusion of the retinal artery). If true, a switch to bedtime prescribing would have more impact on the health of hypertensive Canadians than whether high BP is treated at all.
And yet this trial failed to change practice. This is because 1) most health care providers are unaware of the MAPEC trial and 2) replication of such surprising results is required for these findings to be believed – primarily because the benefit seems "too good to be true", far exceeding all other methods of cardiovascular risk reduction (e.g. high dose statins convey a 35% relative risk reduction, morning BP meds 30%, exercise 25%, aspirin 15%). At the time BedMed began recruiting, neither relatively recent (Oct 2013) literature review, nor a 2011 Cochrane systematic review had found ANY RCTs (besides MAPEC) evaluating the effect of BP medication timing on “hard” endpoints7,8. Since that time, the MAPEC authors have published a second trial that again suggests a large benefit to bedtime antihypertensive prescribing9. However, no independent validation of these findings have yet been published. Another independent evaluation of MAPEC is being carried out in the United Kingdom, with results anticipated in summer 2022.10
BedMed completed recruitment in June 2022, and will follow those individuals until late 2023. At that point we anticipate observing the same number of primary outcome events (254) as were reported in the MAPEC trial. The BedMed final analysis will be completed in spring 2024, with results to be disseminated soon thereafter.
The BedMed Initiative is supported in Alberta by a 3 year, $1,191,998 Partnership for Research & Innovation in the Health System (PRIHS) award from Alberta Innovates - Health Solutions (AIHS).
The BedMed Initiative is supported outside of Alberta by a 4 year $1,420,736 SPOR Innovative Clinical Trials Multi-Year Grant from Canadian Institutes of Health Research (CIHR).
The BedMed Initiative is also supported in-kind by EnACt.